Related Experiment Video

Updated: Aug 22, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

CRIPTO-1: a novel target for therapeutic intervention in human carcinoma

Nicola Normanno1, Antonella De Luca, Monica R Maiello

  • 1Department of Experimental Oncology, INT-Fondazione Pascale, Via Mariano Semmola, I-80131 Naples, Italy. nicnorm@yahoo.com

International Journal of Oncology
|September 18, 2004
PubMed

Insights

CRIPTO-1 (CR-1) is expressed in various human carcinomas and drives cancer cell growth. Inhibiting CR-1 with antisense oligonucleotides significantly reduced tumor growth in cell lines and mouse models, suggesting CR-1 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • CRIPTO-1 (CR-1) is implicated in human carcinoma pathogenesis.
  • Understanding CR-1 expression and function is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the expression of CR-1 mRNA and protein in human cancer cell lines.
  • To evaluate the therapeutic potential of targeting CR-1 using antisense oligonucleotides.

Main Methods:

  • Screening CR-1 expression using RT-PCR, real-time PCR, and immunocytochemistry.
  • Assessing the effect of antisense oligonucleotides against CR-1, TGF-alpha, and AR on cancer cell growth.
  • Evaluating the impact of antisense oligonucleotides on Akt activation and tumor xenograft growth in nude mice.

Main Results:

  • CR-1 is expressed across multiple human carcinoma types.
  • Anti-CR-1 antisense oligonucleotides significantly inhibited anchorage-independent growth of colon, ovarian, lung, and breast carcinoma cells.
  • Treatment with CR-1 antisense oligonucleotides reduced CR-1 expression, Akt activation, and xenograft tumor growth.

Conclusions:

  • CR-1 plays a significant role in the proliferation and survival of various carcinoma cells.
  • CR-1 represents a promising novel therapeutic target for diverse carcinoma types.
  • Antisense oligonucleotide-mediated inhibition of CR-1 demonstrates therapeutic efficacy in preclinical models.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...